Women of reproductive age with acromegaly can be interested in pregnancy, even when the pituitary tumor keeps rather big sizes, or control over secretion of GH and IGF-1 has not been reached. In this regard doctors often meet questions of acromegaly influence on the course of pregnancy. Now a little more than 100 cases of pregnancy at acromegalic female patients were described. In article the short review of the cases published in literature is carried out, and a new own clinical case of pregnancy at the patient with acromegaly is represented. The young woman (24 y.o.) received treatment with octreotide prolonged release in a dose 20/40 mg after non-radical adenomectomy for somatoprolactinoma, on this background she became pregnant, and continued medical treatment during all pregnancy. There were no complications during pregnancy and/or pathology of fetal formation. In women with acromegaly treatment with somatostatin analogs is not the indication for pregnancy interruption. It is possible to stop this treatment for the period of pregnancy as such break in treatment is safe for mother and fetus in most cases according to the literature. However if the estimated risk of further growth of a pituitary tumor is high, treatment can be continued during pregnancy.

Achievement and long-term maintenance of optimal glucose control is still a big problem in many patients with type 2 diabetes. Diabetes related complications and cardiovascular diseases also can do more difficult the choice of glucose lowering therapy. Insulin therapy is the most effective method of treatment in such patients. However treatment with human insulin is often associated with hypoglycemia and weight gain, which are additional barriers to achieve glycemic control. Presented clinical cases show that switching from human insulin for insulin analogues detemir (Levemir) and aspart (NovoRapid) provide a significant improvement in glycemic control without increasing of risk of hypoglycemia and weight gain.

DCCT (Diabetes Control and Complications Trial) study showed that intensified insulin therapy associates with significant reduction both of development and progression of vascular complications compared to conventional insulin therapy in type 1 diabetic patients. Modern algorithms of diabetes treatment in children and adolescents reflect the need to achieve and maintenance of glycemic control as closely as possible to normal level. Insulin analogues have improved pharmacokinetic and pharmacodynamic properties, and also have less variability than human insulin. So they have more physiologic and predictable profile actions and, therefore, provide the possibility to achieve optimal glycemic control with low risk of hypoglycemia. Current review demonstrates the benefits of basal-bolus therapy with insulin analogues detemir (Levemir) and aspart (NovoRapid) and advantages of insulin NovoRapid in the continuous subcutaneous insulin infusion (CSII) compared with human insulin in children and adolescents with type 1 diabetes mellitus.